We are live on ! Find out more
FOMX

Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX

Delisted

FOMX was delisted on the 6th of March, 2020.

Back to rankings

66 hedge funds and large institutions have $116M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 25 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% less funds holding

Funds holding: 75 → 66 (-9)

16% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 25

18% less call options, than puts

Call options by funds: $145K | Put options by funds: $177K

39% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 18

41% less capital invested

Capital invested by funds: $197M → $116M (-$80.7M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
66
Holders Change
-9
Holders Change %
-12%
% of All Funds
1.47%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
11
Increased
21
Reduced
25
Closed
18
Calls
$145K
Puts
$177K
Net Calls
-$32K
Net Calls Change
-$406K

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$7.51M
2
PA
Perceptive Advisors
New York
+$6.76M
3
SM
Senvest Management
New York
+$3.29M
4
SCM
Stonepine Capital Management
Oregon
+$3.23M
5
Man Group
Man Group
United Kingdom
+$1.85M

Top Sellers

Rank Fund Capital Flow
1
DA
DSC Advisors
Illinois
-$9.86M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$6.62M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$6.3M
4
NC
Nexthera Capital
New York
-$4.28M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$18.7M – – –
PA
2
Perceptive Advisors
New York
$15.8M +$6.76M +1,554,400 +50%
GPP
3
Great Point Partners
Connecticut
$14.5M +$75.2K +17,293 +0.4%
Franklin Resources
4
Franklin Resources
California
$9.42M +$1.32M +302,700 +13%
UBS Group
5
UBS Group
Switzerland
$6.22M +$7.51M +1,725,874 +24,230%
Axa
6
Axa
France
$4.85M -$80K -18,403 -1%
SCM
7
Stonepine Capital Management
Oregon
$4.64M +$3.23M +742,099 +135%
SCM
8
Sio Capital Management
New York
$4.13M +$1.66M +381,510 +50%
Millennium Management
9
Millennium Management
New York
$3.78M -$437K -100,387 -9%
SI
10
Sofinnova Investments
California
$2.99M +$712K +163,674 +24%
DCM
11
DAFNA Capital Management
California
$2.9M – – –
SM
12
Senvest Management
New York
$2.71M +$3.29M +755,998 New
Handelsbanken Fonder
13
Handelsbanken Fonder
Sweden
$2.3M – – –
BlackRock
14
BlackRock
New York
$2.23M +$618K +142,159 +30%
TCM
15
Tekla Capital Management
Massachusetts
$2.16M -$548K -126,000 -17%
First Manhattan
16
First Manhattan
New York
$1.83M -$465K -107,000 -17%
BBA
17
Baker Bros. Advisors
New York
$1.79M -$826K -189,886 -28%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$1.66M -$751K -172,616 -27%
CWG
19
C WorldWide Group
Denmark
$1.59M -$683K -157,116 -26%
Man Group
20
Man Group
United Kingdom
$1.53M +$1.85M +425,278 New
DAM
21
DLD Asset Management
New York
$1.08M +$1.3M +300,000 New
EP
22
Eversept Partners
New York
$1.06M +$90.6K +20,843 +8%
DCM
23
Diag Capital Management
New York
$960K +$637K +146,432 New
Baillie Gifford & Co
24
Baillie Gifford & Co
United Kingdom
$787K – – –
DMK
25
David M. Knott
$740K +$897K +206,200 New
1
2 3 4

FOMX Hedge Fund Activity: Q4 2018 in Review

66 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q4 2018, worth a combined $116M — down 41% from $197M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of FOMX and 11 opened new positions — a net loss of 7 holders — while 25 trimmed existing stakes and 21 added.

The largest buyer was UBS Group, adding an estimated $7.51M. The largest seller was DSC Advisors, exiting entirely with an estimated $9.86M sold.

  • 66 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q4 2018, down from 75 in Q3 2018.
  • Funds reported $116M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q4 2018, down 41% quarter-over-quarter.
  • 11 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q4 2018 and 18 closed out, a net change of -7 holders.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q4 2018 was UBS Group, an estimated $7.51M added.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q4 2018 was DSC Advisors, an estimated $9.86M sold.

Based on aggregated 13F filings for Q4 2018.